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Host innate immune response follows severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection, and it is the driver of the acute respiratory distress syndrome
(ARDS) amongst other inﬂammatory end-organ morbidities. Such life-threatening
coronavirus disease 2019 (COVID-19) is heralded by virus-induced activation of
mononuclear phagocytes (MPs; monocytes, macrophages, and dendritic cells). MPs
play substantial roles in aberrant immune secretory activities affecting profound systemic
inﬂammation and end-organ malfunctions. All follow the presence of persistent viral
components and virions without evidence of viral replication. To elucidate SARS-CoV2-MP interactions we investigated transcriptomic and proteomic proﬁles of human
monocyte-derived macrophages. While expression of the SARS-CoV-2 receptor, the
angiotensin-converting enzyme 2, paralleled monocyte-macrophage differentiation, it
failed to affect productive viral infection. In contrast, simple macrophage viral exposure
led to robust pro-inﬂammatory cytokine and chemokine expression but attenuated type I
interferon (IFN) activity. Both paralleled dysregulation of innate immune signaling
pathways, speciﬁcally those linked to IFN. We conclude that the SARS-CoV-2-infected
host mounts a robust innate immune response characterized by a pro-inﬂammatory storm
heralding end-organ tissue damage.
Keywords: macrophages, SARS-CoV-2, cytokine storm, interferon, end-organ disease, inﬂammation,
transcriptomics, proteomics

INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus
disease 2019 (COVID-19), is an enveloped positive-stranded RNA virus belonging to the
Coronaviridae family, Betacoronaviruses genus (1). COVID-19 has posed an unprecedented
global threat to public health, and in March of 2020, it was declared a pandemic by the World
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pathways, complement activation, and linked adaptive immune
responses. All provide unique insight into how the inﬂammatory
response occurs as a consequence of SARS-CoV-2 infection.
Virion persistence for up to 14 days after viral exposure despite
restrictive infection underlies the persistence of immune
activation. Most importantly, the data provides a signature for
virus-induced disease pathobiology, including COVID-19associated CSS and multiorgan dysfunction. All affect the most
severe disease morbidities and mortalities seen as a consequence
of viral exposure, transmission, and dissemination.

Health Organization (WHO) (2). COVID-19 ranges from
asymptomatic infection to mild pneumonia and, in its most
severe form, progression to acute respiratory distress syndrome
(ARDS). Such pulmonary compromise is associated with
dyspnea and hypoxia that can progress to severely
compromised lung dysfunction and multiorgan system failure
and death (3). Disease mortality is linked to cytokine storm
syndrome (CSS), heralded by innate immune activation with the
secretion of excessive pro-inﬂammatory cytokines (4). Indeed,
nearly 15% of reported COVID-19 disease cases progress to
ARDS deﬁned by widespread inﬂammatory-associated lung
tissue damage and multiorgan failure (5) involving heart, liver,
gastrointestinal tract, kidney, and brain (6). Viral persistence in
the face of such end-organ disease is linked to cell expression of
angiotensin-converting enzyme 2 (ACE2), the molecule that
SARS-CoV-2 utilizes for receptor-mediated cell entry (7).
Mononuclear phagocytes (MPs; monocytes, macrophages,
and dendritic cells) are the governors of innate immunity
serving to contain microbial infection (8). Immediately
following viral exposure, the process of intracellular microbial
removal is initiated through recognition of viral pathogenassociated molecular patterns (PAMPs) by pattern recognition
receptors (PRRs). This includes, but is not limited to, cytosolic
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and
extracellular and endosomal toll-like receptors (TLRs). During
the initiation of virus-cell interactions, secretion of proinﬂammatory cytokines and chemokines initiate intracellular
killing, antigen presentation, and mobilization of adaptive
immunity. Factors that are engaged include, but are not
limited to, interleukin-6 (IL-6), IL-1, tumor necrosis factoralpha (TNF-a), and C-X-C motif chemokine ligand 10
(CXCL10) (9). Type I interferon (IFN) a and b responses
occur in tandem to control both viral replication and
dissemination (10). During infection with SARS-CoV-2, CSS
contributes to COVID-19-associated multiorgan failure (11, 12).
In particular, inﬁltrating inﬂammatory MPs in lungs, heart,
kidney, spleen, and lymph nodes are seen in post-mortem
tissues of COVID-19-infected patients (13–16). Despite the
critical role of MPs to clear the infection, these same cells
underlie the pathobiology of COVID-19.
Mounting evidence conﬁrms abortive MP infection by SARSCoV-2 (17, 18). Nonetheless, such viral cell engagements are
sufﬁcient to induce activation and pro-inﬂammatory cytokine
secretory responses. The nature of virus-MP interactions and
their role in abortive viral infection and associated tissue
pathologies remains enigmatic. To such ends, we pursued
transcriptomic and proteomic analyses of immune cells
following virus infection to identify modulations of host
immune responses. We employed MPs to assess immune
responses following SARS-CoV-2 cell engagements for cell
activation using human immune response arrays and mass
spectrometry-based label-free proteomic quantiﬁcation
methods. These techniques serve to deﬁne virus-induced
innate immune responses linked to antiviral immunity. Based
on these tests, we have uncovered the dysregulation of a
spectrum of viral-induced responses related to IFN signaling
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MATERIALS AND METHODS
Isolation and Cultivation of
Human Monocytes
Human monocytes were obtained by leukapheresis from
hepatitis B and HIV-1/2 seronegative donors and puriﬁed by
counter-current centrifugal elutriation (19). Monocytes were
seeded in 6-well plates (3x10 6 cells/well) in Dulbecco’s
Modiﬁed Eagle’s Media (DMEM) containing 4.5 g/l glucose, Lglutamine, and sodium pyruvate, and supplemented with 10%
heat-inactivated human serum, 50 mg/ml gentamicin, 10 mg/ml
ciproﬂoxacin, and 1000 U/ml human macrophage colonystimulating factor (M-CSF) to facilitate differentiation of
monocytes into monocyte-derived macrophages (MDMs). Cells
were incubated at 37°C with 5% CO2, and the culture medium
was half-exchanged with fresh medium every other day (20).

Flow Cytometry Assays
Human monocytes were evaluated by ﬂow cytometry for levels of
SARS-CoV-2 cell entry receptor ACE2 and monocytemacrophage phenotypic surface markers, CD14 and CD16,
during macrophage differentiation with or without captopril
(Sigma-Aldrich, C4042). Captopril was added to the culture
medium to increase ACE2 cell expression. On days 0, 1, 3, 5,
and 7 during differentiation, monocytes-macrophages were
stained with ﬂuorescently-conjugated antibodies to detect
human ACE2 (APC, LSBio, LS−C275129, polyclonal), CD14
(Alexa Fluor 488, eBioscience, clone 61D3), and CD16 (PE,
eBioscience, eBioCB16, clone CB16), and with isotype-matched
antibodies serving as negative controls. Stained cells were
examined with an BD LSR II ﬂow cytometer (BD Biosciences)
and analyzed using BD FACSDiva software.

SARS-CoV-2 Infection
Experiments involving SARS-CoV-2 were performed in the
University of Nebraska Medical Center (UNMC) biosafety
level 3 (BSL-3) core facility and approved by UNMC
Institutional Biosafety Committee (IBC) (protocol number 2005-027-BL3). The SARS-CoV-2 strain used in this study was
isolate USA-WI1/2020 (BEI, NR-52384) unless stated otherwise.
The virus was passaged on Vero.STAT1 knockout (KO) cells
(ATCC, CCL-81-VHG) and titer was determined by plaque
assay in Vero E6 cells (ATCC, CRL-1586) (21). The selection
of multiplicity of infection (MOI) for the following experiments
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Forward primer: 5’ GACCCCAAAATCAGCGAAAT 3’,
Reverse primer: 5’ TCTGGTTACTGCCAGTTGAATCTG 3’,
and Probe: 5’ FAM-ACCCCGCATTACGTTTGGTGGACCBHQ-1 3’. RT-qPCR was performed using Taqman Fast Virus
1-step Master Mix (Thermo Fisher Scientiﬁc, 4444434) in
StepOne Plus real-time PCR thermocycler (Applied
Biosystems) using the following cycling conditions: 50°C for 10
minutes, 95°C for 3 minutes, and 40 cycles of 95°C for 15
seconds, followed by 60°C for 1 minute. The SARS-CoV-2
genome equivalent copies were calculated using control RNA
from heat-inactivated SARS-CoV-2 USA-WA1/2020 (BEI,
NR-52347).

was made based on a pilot experiment using isolate USA-WA1/
2020 (BEI, NR-52281). Human MDMs were challenged at
increasing MOIs of 0.001, 0.01, and 0.1. The SARS-CoV-2 and
mock-treated MDMs and culture ﬂuids were collected from days
1 to 11 after viral exposures. Total RNA was isolated using
RNeasy Mini Kit (Qiagen, 74104), and cDNA was generated
utilizing RevertAid First Strand cDNA synthesis kit (Thermo
Fisher Scientiﬁc, K1622) followed by ampliﬁcation and
quantiﬁcation using RT2 Proﬁler Human Innate and Adaptive
Immune Response 96-well Array (Qiagen, 330231) with RT2
SYBR Green ROX qPCR Mastermix (Qiagen, 330523). The
qPCR cycling conditions were 95°C for 10 minutes for 1 cycle,
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1
minute using Eppendorf Mastercycler ep realplex 2S. Fold
changes were determined by Qiagen’s RT2 proﬁler analysis
software (version 3.5). Based on the transcriptomic data of day
11 after viral exposure, the viral exposure was repeated using
MDMs isolated from different donors with the WA1/2020 viral
strain administered at an MOI of 0.01. The transcriptomic proﬁle
of SARS-CoV-2 and mock-treated MDMs was assessed on day 4
after viral exposure. Based on the transcriptomic data of day 4,
the MOI of 0.01 was selected. Five days following cell cultivation
MDMs were exposed to the WI1/2020 viral strain at an MOI of
0.01. Exposure was maintained with or without captopril, and
the virus-cell mixtures incubated at 37°C in 5% CO2 with
shaking at 15-minute intervals for 1 hour. This was followed
by incubation with the virus for an additional 3 hours. At the
termination of viral cell incubation, the virus inoculum was
removed, and cells were washed 3 times with phosphatebuffered saline (PBS). Mock-challenged cells were treated with
a culture medium alone. Culture supernatants were collected at
deﬁned time points then used for viral quantitative reverse
transcription-polymerase chain reaction (RT-qPCR) and type I
IFN activity assays. Vero.STAT1 KO cells were maintained for
study based on their high susceptibility to virus infection due to
lack of Signal Transducer and Activator of Transcription 1
(STAT1) protein required for cellular antiviral responses (22).
Thus, the SARS-CoV-2 replication kinetics in MDMs were
compared against viral infection in Vero.STAT1 KO cells that
were monitored over 5 days post-viral exposure.

Transmission Electron Microscopy
For negative staining analysis of viral particles used for cell
infection experiment, puriﬁed SARS-CoV-2 viruses were deac ti va te d a nd ﬁ x e d in 2 % gl u t a r a l d e h y d e a n d 2 %
paraformaldehyde (PFA) in 0.1 M Sorenson’s phosphate buffer
for 1 hour at room temperature. Brieﬂy, for negative staining, a
drop of the virus sample in a ﬁxative solution was placed onto a
formvar and carbon-coated grid for 30-40 seconds. After
removing excess sample solution with ﬁlter paper, the grid was
placed with sample side down on a drop of 1% phosphotungstic
acid (PTA) in water, stained for 30 seconds, then excess PTA
solution was blotted with ﬁlter paper. Stained samples were
examined and imaged using a Hitachi H7500 TEM (Hitachi
High-Tech GLOBAL) and a bottom-mount AMT camera (AMT
Imaging). For ultrastructural analysis, mock and SARS-CoV-2challenged MDMs sampled at 1, 3, 5 and 14 days post-viral
inoculation were washed 2 times with PBS and ﬁxed in a solution
of 2% glutaraldehyde and 2% PFA in 0.1 M Sorenson’s
phosphate buffer for 24 hours at 4°C which have been washed
3 times with PBS to clear excess ﬁxative solution. TEM analysis
was performed as previously described (23) in samples post-ﬁxed
in a 1% aqueous solution of osmium tetroxide for 30 minutes
that were dehydrated in 50, 70, 90, 95, and 100% graded ethanol.
Spurr’s resin was used as embedding medium after solvent
transition with ethanol and Spurr’s resin (50:50 ethanol:resin,
followed by twice immersion in 100% Spurr’s resin for 2-3 hours
for each solution), and embedded samples were cured at 60 65°C for 24 hours. Ultrathin sections (100 nm) were cut with Leica
UC7 ultramicrotome, placed on 200-mesh copper grids, followed
by staining with 2% uranyl acetate and Reynold’s lead citrate, and
examined with a Hitachi H7500 TEM at 80 kV. Images were
acquired digitally with an AMT digital imaging system.

RT-qPCR Assay
Total RNA was extracted from the infected MDMs on days 1, 3,
5, 7, and 10 following viral exposure, followed by quantiﬁcation
for SARS-CoV-2 genome equivalents by RT-qPCR, and the gene
expression was normalized to HPRT1 (Thermo Fisher Scientiﬁc,
4331348). Forward primer: 5’ GGACTAATTATGGACA
GGACTGAA 3’, Reverse primer: 5’ ACAGAGGGCTACAA
TGTGATG 3’, and Probe: 5’ FAM-AGATGTGATGAAGG
AGATGGGAGGC-BHQ-1 3’and presented as fold change in
gene expression of infected cells relative to mock-challenged
cells. After viral exposure, culture supernatants were collected on
days 1, 3, 5, 7, and 10. Viral RNA was extracted using QIAamp
Viral RNA Mini Kit (Qiagen, 52906). SARS-CoV-2 genome
equivalents were quantiﬁed in culture supernatant by RTqPCR using 2019-nCoV CDC probe and Primer Kit for SARSCoV-2 (Biosearch Technologies, KIT-nCoV-PP1-1000).
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Transcriptomic Analyses
SARS-CoV-2 and mock-challenged MDMs were collected on
days 1, 3, and 5. Total RNA was isolated, and cDNA was
synthesized, then ampliﬁcation and quantiﬁcation using an
RT2 Proﬁler Human Innate and Adaptive Immune Response
96-well Array, and fold changes were determined by Qiagen’s
RT2 Proﬁler analysis software. Ingenuity Pathway Analysis (IPA)
(Qiagen) was used to identify the pathways and networks
affected post-viral exposure. Functional and pathway
enrichment analyses of screened genes in SARS-CoV-2challenged MDMs were compared to mock-challenged MDMs
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incubation in 3% nonfat milk in Tris-buffered saline with 0.1%
Tween 20 detergent (TBST) buffer with horseradish peroxidaseconjugated anti-rabbit (1:2000, R&D Systems, HAF008) or
mouse (1:2000, R&D Systems, HAF018) secondary antibody.
Immunoreactive bands were detected using SuperSignal West
Pico Chemiluminescent substrate (Thermo Fisher Scientiﬁc,
34080), and images were captured using an iBright CL750
Imager (Thermo Fisher Scientiﬁc). Immunoblots were
quantiﬁed using ImageJ software (NIH) relative to bactin expression.

at different time intervals following viral exposure. Gene
ontology (GO) annotation was conducted with GO Resource
database (http://geneontology.org). The Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment analysis was
conducted utilizing DAVID (http://david.abcc.ncfcrf.gov/) (24),
an online tool providing a comprehensive set of functional
annotations providing biological meaning to the gene lists. The
gene set enrichment analysis (GSEA) was conducted using
ReactomeFIViz (https://reactome.org/tools/reactome-ﬁviz) (25),
a Cytoscape application for pathway and network-based data
analyses. The Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) local network cluster enrichment
was conducted using the STRING database (http://string-db.
org), which provides critical assessments and integration of
protein-protein interaction (PPI). This includes direct
(physical) and indirect (functional) associations in a given
organism (26).

Proteomic Analysis
On days 1, 3, and 5 post-infection, MDMs were collected, lysed
with 2% SDS in 100 mM Tris-HCL and 100 mM dithiothreitol,
pH 7.6, and supplemented with protease and phosphatase
inhibitors. Protein concentration was determined using Pierce
660 Protein Assay kit with ionic detergent compatibility reagent
according to the manufacturer’s instructions. Afterward, samples
were processed as previously described (29) using ﬁlter-aided
sample preparation (FASP, Pall Life Sciences, OD010C34) to
digest 50 mg per sample. Following overnight digestion, samples
were cleaned using the Oasis MCX column (Waters, 186000252)
and C18 Zip-Tips (Sigma-Aldrich, ZTC18M960). Cleaned
peptides were quantitated using NanoDrop2000 at 205 nm.
Following resuspension in 0.1% formic acid, 2 mg of the
sample was used for label-free quantiﬁcation (LFQ) in UNMC
Mass Spectrometry and Proteomics Core Facility as previously
described (30). Protein identiﬁcation was performed by
searching MS/MS data against the swiss-prot homo sapiens
and SARS-CoV-2 protein databases downloaded on April 2021
and August 2021, respectively, using the in-house PEAKS X +
DB search engine. The search was set up for full tryptic peptides
with a maximum of 2 missed cleavage sites. Acetylation of
protein N-terminus and oxidized methionine were included as
variable modiﬁcations, and carbamidomethylation of cysteine
was set as ﬁxed modiﬁcation. The precursor mass tolerance
threshold was set 10 ppm for, and the maximum fragment
mass error was 0.02 Da. The signiﬁcance threshold of the ion
score was calculated based on a false discovery rate (FDR) of ≤
1%. Quantitative data analysis was performed to determine
differentially expressed proteins between mock and SARSCoV-2-challenged MDMs at different time points after viral
exposures using Progenesis QI Proteomics 4.2 (Nonlinear
Dynamics). Statistical analysis was performed using ANOVA
and FDR for pathway analysis. This was controlled using the
Benjamini-Hochberg (BH) method (31). A protein was
differentially expressed if p value ≤ 0.05 and the absolute value
of fold change ≥ 2. Functional and pathway enrichment analysis
of differentially expressed proteins in SARS-CoV-2-challenged
MDMs compared to mock-challenged MDMs was conducted at
different time points after the virus challenge. Gene enrichment
analysis to identify immune system processes affected after virus
exposure was performed using Cytoscape in conjunction with
the plug-in ClueGO (32). GO annotation, KEGG, Reactome
GSEA, and STRING analyses were conducted using GO
Resource, DAVID, ReactomeFIViz, and STRING databases,

Measures of IFN Activity
MDBK cells (ATCC, CCL-22) were cultured in Eagle’s Minimum
Essential Medium (EMEM) containing 10% heat-inactivated
fetal bovine serum (FBS) and 50 µg/ml gentamicin (27).
Vesicular stomatitis virus (VSV Indiana laboratory strain) (V520-001-522, ATCC, VR-1238) was passaged on Vero cells
(ATCC, CCL-81), and viral titer was determined using the
plaque assay in Vero cells. MDBK cells bind and respond to
human type I IFNs, a and b, but not IFN-gamma (IFN-g) (27).
Culture supernatants were collected from virus-exposed MDMs
on days 1, 3, and 5 following infection with SARS-CoV-2 at MOI
of 0.01, then assessed for IFN-a/b activity by protection against
the VSV-induced cytopathicity measured in MDBK cells (27).
Polyinosinic-polycytidylic acid (poly(I:C); Sigma-Aldrich,
P9582) served as a positive control for IFN induction via TLR3
engagement (28). Recombinant human IFN-a (PBL Assay
Science, 11200-2) was used as assay standard. We also
investigated IFN activity upon the challenge of Teﬂon ﬂasksuspended monocytes with SARS-CoV-2 (MOI=0.01), before
and after treatment of cells with 100 µg/ml poly(I:C).

Western Blot Analysis
At days 1, 3, and 5 after infection, MDMs were collected, and
total protein was extracted using lysis buffer containing 0.1%
SDS, 100 mM Tris-HCL, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, supplemented with protease and phosphatase inhibitor
cocktail (Sigma-Aldrich, PPC1010). Protein concentration was
determined utilizing Pierce 660 Protein Assay kit (Thermo
Fisher Scientiﬁc, 22662) with ionic detergent compatibility
reagent (Thermo Fisher Scientiﬁc, 22663) following the
manufacturer’s instructions. Protein lysates (25 mg) were
resolved by SDS-PAGE and transferred to Immobilon-P PVDF
membrane (Sigma-Aldrich, IPVH00010). Membranes were
blocked in 5% nonfat milk in TBST buffer at room
temperature for 1 hour, followed by incubation with primary
antibodies to IFN-a (1:500, Thermo Fisher Scientiﬁc, MA537518), IFN-b (1:1000, Abcam, ab85803), and b-actin (1:3000,
Sigma-Aldrich, A3854) at 4°C overnight, followed by 1 hour
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respectively. Overlapping genes between transcriptomic and
proteomic data were identiﬁed and represented in
Venn diagrams.

we posit that they can increase susceptibility to SARS-CoV-2.
Therefore, we measured ACE2 expression on freshly isolated
monocytes throughout cell isolation and differentiation. Days 1,
3, 5, and 7 were evaluated for cells cultured with or without
captopril, an ACE inhibitor which is thought to increases ACE2
expression. In these studies, ACE2 expression by monocytes was
found to peak by day 5 after initiation of cell differentiation then
decreased after that (Figure 1A), which corresponds to the
susceptibility of infection of monocytes-macrophages by other
viruses (20, 36, 37). On day 5, ACE2 expression increased by 23%
in captopril-treated cells (p = 0.24). In parallel, the expression of
phenotypic monocyte-macrophage surface markers, CD14 and
CD16, were not changed (Figure 1A). Representative ﬂow
cytometry histograms for ACE2, CD14, and CD16 expression
are shown in Supplementary Figure 1. Based on these
observations, we challenged MDMs with SARS-CoV-2 on day
5 after the start of cell differentiation and assessed whether
captopril affects susceptibility to infection.

Correlation Analysis of Transcriptomic and
Proteomic IFN Pathway Genes
The parametric Pearson’s product moment correlation analysis
between transcriptomic and proteomic data for day 1, 3, and 5time points were conducted for 10 IFN pathway-related genes.
The correlation coefﬁcient (r) for each gene was calculated.

Statistical Analysis
Results are presented as the mean ± standard error of the mean
(SEM). Student’s t-test or one-way ANOVA followed by Tukey’s
multiple comparison test was used to analyze differences in the
mean values between groups. P values ≤ 0.05 were considered
statistically signiﬁcant. Statistical analysis was performed using
GraphPad Prism 9.1.0 software (GraphPad Software, San
Diego, CA).

SARS-CoV-2 MOI Determinations
To select the MOI of 0.01, pilot experiments were done screening
several infectious parameters. MOIs of 0.001, 0.01, and 0.1 were
chosen in these experiments to challenge the MDMs with
consequent monitoring of signs of productive infection. The
“putative” growth of the SARS-CoV-2 in MDMs was then
determined by evaluating the culture supernatants over 11 days
after viral exposures. At varied MOIs, the number of genome
copies remained unchanged over time. This indicated restrictive

RESULTS
ACE2 Receptor Expression During Human
Monocyte-Macrophage Maturation
ACE inhibitors were used to upregulate the SARS-CoV-2
receptor ACE2 and potentiate cell entry (33–35). As ACE
inhibitors are frequently prescribed to treat hypertension,

A

B

C

FIGURE 1 | SARS-CoV-2 restrictive infection of human MDMs. (A) Expression of SARS-CoV-2 cell entry receptor ACE2 and phenotypic surface markers CD14 and
CD16, during differentiation of monocytes into macrophages, was analyzed by ﬂow cytometry in absence or presence of captopril. (B) SARS-CoV-2 presence in
MDMs. SARS-CoV-2 (MOI=0.01) was used to infect MDMs (with or without captopril). The number of virus genome equivalents per ml was measured in cell lysates
and culture supernatants by RT-qPCR. Vero.STAT1 KO cells served as a positive control. (C) Transmission electron micrographs of SARS-CoV-2-challenged MDMs.
(C.i) A viral particle from a pool of SARS-CoV-2 used for the virus challenges. SARS-CoV-2-challenged MDMs [(C.ii) day 5, and (C.iii) day 14 after viral exposure].
Red arrows, circles, and boxes demonstrate clusters of viral particles within the virus-challenged macrophages. All experiments were done at least twice with
representative images depicted here. (A, B) Data are represented as mean ± SEM (n=3-6 donors). Statistical signiﬁcance between groups was determined using
one-way ANOVA, and p < 0.05 was considered signiﬁcant (*signiﬁcantly different from day 0 w/o captopril, a: signiﬁcantly different from day 1 w/o captopril, b:
signiﬁcantly different from day 5 w/o captopril, aw: signiﬁcantly different from day 1 with captopril, bw: signiﬁcantly different from day 3 with captopril, cw: signiﬁcantly
different from day 5 with captopril). w/o: without. Scale bars: 50 nm (i and left panel of iii), 100 nm (left panel of ii), and 400 nm (right panels of ii and iii).
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mature virions were observed 14 days after initial exposure
(Figure 1C.iii). These underlie the persistence of virus in
macrophages despite evidence of restrictive infection.

viral infection without evidence of viral replication
(Supplementary Figure 2). However, the transcriptomic
proﬁle of SARS-CoV-2-challenged MDMs (MOI=0.01) showed
more than 5-fold increase in gene expression of proinﬂammatory cytokines and chemokines up to day 11. This
included IL1B, IL1R1, chemokine (C-C motif) ligand 8 (CXCL8),
and CCL2 (78.56, 40.11, 6.48, 81.33-fold, respectively)
(Supplementary File 1). The MOI used for these experiments
were held constant at 0.01. For these analyses, we challenged
MDMs with SARS-CoV-2 then analyzed the cell’s transcriptomic
proﬁle on day 4 after viral exposure. In this replicate experiments, a
more than 2-fold increase in expression of IL17A, IL18, IL1B,
CXCL8, NLRP3, and TLR8 was recorded (p = 0.39, 0.27, 0.34,
0.28, 0.18, 0.34, respectively) (Supplementary File 2). Additionally,
the data showed, in parallel, a more than 2-fold increase in select
IFN-related genes that included IFNA1, IFNGR1, IRF3, IFN
regulatory factor 7 (IRF7), and tyrosine kinase 2 (TYK2) (p = 0.1,
0.19, 0.35, 0.26, and 0.29, respectively) (Supplementary File 2).
Based on these observations, we conﬁrmed the MOI of 0.01 in
eliciting a cell-based activation proﬁle.

Persistent SARS-CoV-2 Components in
MDMs Induce Pro-Inﬂammatory Factors,
but Not IFN
To investigate alterations in macrophage-mediated innate immune
responses after SARS-CoV-2 exposure, a total of 84 key genes were
examined. Transcriptional changes linked to immunity were
screened using RT2 Proﬁler Human Innate and Adaptive
Immune Response Array. Expression of immune response genes
in SARS-CoV-2-challenged MDMs were investigated against
control “mock-challenged cells” on days 1, 3, and 5
(Supplementary Figure 3 and Supplementary File 3). On day 1,
more than 2-fold increase in expression of pro-inﬂammatory
cytokine and chemokine genes were detected, including IL-6 (p =
0.32), TNF-a (p = 0.32), IL-1a (p = 0.98), IL17A (p = 0.38), IL8 (p =
0.08), colony-stimulating factor 2 (CSF2) (p = 0.37), chemokine (CC motif) ligand 2 (CCL2) (p = 0.32), and CCL5 (p = 0.32).
Interestingly, on day 3, gene expression of the node-like receptor
family pyrin domain containing 3 (NLRP3) and IL-1b increased by
8.84- and 5.64-fold, respectively (p = 0.98 and 0.78, respectively). On
day 5, expression for these pro-inﬂammatory cytokines and
chemokines were at baseline or decreased with the exception of
IL-6 and CCL2 (p = 0.91 and 0.65, respectively). Notably, on day 5
after viral exposure there was an upregulation of STAT1 gene
expression (4.1-fold, p = 0.71), IFNAR1 gene expression (2.64fold, p = 0.17), and MX1 as an IFN-stimulated gene (2.68-fold, p =
0.56). MX1 has been shown to have wide antiviral activity against
RNA and DNA viruses by its direct effect on the viral
ribonucleoprotein complex and its GTPase activity essential for
SARS-CoV-2 replication (38). Additionally, on day 5 after viral
exposure, there was a slight upregulation of TLR8 gene expression
(1.68-fold, p = 0.41), supporting the pro-inﬂammatory environment
in SARS-CoV-2-challenged MDMs (39) sustained to day 5 after
viral exposures. There are dual regulatory activities between
inﬂammatory and a compensatory anti-inﬂammatory response as
shown through IL-10, IL-4, and IL-13. This dual regulatory
phenotype of the macrophages is depicted with shown data sets
for IL-4 (7.82-fold, p = 0.095) and IL-13 (7.06-fold, p = 0.066) (40,
41). Such gene expression for this class of cytokines was shown at
day 4 following the viral exposure (Supplementary File 2).
Moreover, the gene expression of anti-inﬂammatory cytokine IL10 was elevated on days 1 and 5 (3.1 and 3.62-fold, p = 0.34 and
0.22, respectively), supporting the attenuation of pro-inﬂammatory
responses. Importantly, expression of IFN-linked genes IFN-a1,
IFN-b1, IFN-g, IRF7, and TYK2 genes increased more than 2-fold
(p = 0.18, 0.38, 0.35, 0.69, and 0.38, respectively) on day 1 but
returned to near baseline by days 3 and 5. We posit that nonsigniﬁcant p values underlie the divergent clinical responses to
SARS-CoV-2 infection. As can be observed we used the identical
experimental approach with different donors and viral strains and
while each showed an upregulation of pro-inﬂammatory cytokine
and chemokine gene expression the levels recorded were variable
dependent on each of the variables. Those variables included the

Persistence of Viral Components and
Virions in MDMs Is Established Following
SARS-CoV-2 Exposure
To investigate whether human MDMs are susceptible to SARSCoV-2 infection, monocytes were isolated from healthy donors
and differentiated in the presence or absence of captopril and
infected at day 5 after cell culture. The kinetic growth of SARSCoV-2 in MDMs was determined from in cell lysates and culture
supernatant tests of challenged cells over 10 days post-infection.
In the cell lysates (captopril-treated and controls), the SARSCoV-2 genome equivalent copies were not altered up to 10 days
after MDM viral exposures (Figure 1B). In all studied groups
(captopril-treated and controls), the SARS-CoV-2 genome
equivalent copies in the supernatant signiﬁcantly decreased
during 5 days of viral exposure, becoming undetectable after
that (Figure 1B). Additionally, the number of genome copies did
not change signiﬁcantly with or without captopril. These results
demonstrated that SARS-CoV-2 infection of human MDMs was
restrictive without evidence of viral replication and differentiated
monocytes could not generate progeny virus in contrast to
productive infection of SARS-CoV-2 in Vero.STAT1 KO cells
(Figure 1B). Our data also indicated that captopril did not alter
the susceptibility of MDMs to SARS-CoV-2 infection.

Ultrastructural Features of SARS-CoV-2Challenged MDMs
Viral particles and mock and SARS-CoV-2-challenged MDMs
were ﬁxed at different time points after viral exposure and then
examined by TEM to determine ultrastructural changes in the
virus-challenged cells (Figure 1C.i-iii). Negative stain TEM
shows the ultrastructure of a viral particle from a pool of
SARS-CoV-2 used for the virus challenges (Figure 1C.i). By
day 5 after exposure, a cluster of viral particles was shown in the
challenged macrophages (Figures 1C.ii). Surprisingly, while no
viral genome copies were detected after 5 days (Figure 1B),
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In addition, a series of inﬂammation-related processes were
enriched, including inﬂammatory response, positive regulation
of cytokine production, and cellular response to cytokine
stimulus (Figure 2B), highlighting inﬂammation responses
induced after viral exposure. Similarly, different immune and
inﬂammation-related molecular functions such as cytokine
activity, chemokine activity, complement component C1q
binding, type I IFN receptor binding, and IL-1 receptor
binding were enriched after virus exposure (Supplementary
File 4). Furthermore, KEGG pathway analysis showed
enrichment of TLR, NOD-like receptor, and RLR signaling
pathways (Figure 2B), suggesting the activation of PRRs on
MDMs to recognize viral PAMPs initiating innate immune
responses. Moreover, KEGG pathway analysis depicted
enrichment of IL-17, NF-kB, TNF, and chemokine signaling
pathways (Figure 2B), highlighting different inﬂammatory
pathways induced in the SARS-CoV-2-challenged MDMs.
Interestingly, Reactome analysis revealed enrichment of
multiple IFN-related signaling pathways, including IFN-a/b

donor, the virus and the time after exposures. These data demonstrate
a complex pro- and anti-inﬂammatory network interactions that are
sustained to day 5 with attenuated IFN responses following SARS-CoV-2
exposure (Figure 2A).

Functional and Pathway Enrichment of
Immune Regulated Genes
SARS-CoV-2 infection may induce dynamic changes of
immune-based gene expression in speciﬁc cellular biological
processes and pathways in virus-challenged cells. To assess
these changes, functional and pathway enrichment analyses
were performed on immune-regulated genes screened in
SARS-CoV-2-challenged MDMs compared to controls at days
1, 3, and 5 (Supplementary File 4). Multiple immune processes
were enriched upon viral exposure, including defense response to
other organism, positive regulation of immune system processes,
cell surface receptor signaling pathways, and positive regulation
of immune responses (Figure 2B). All indicated they comprised
activated immune responses in the virus-challenged MDMs.

A

B

FIGURE 2 | Transcriptomic proﬁle of SARS-CoV-2-challenged MDMs. Expression of 84 genes speciﬁc for human innate and adaptive immune responses were
screened in SARS-CoV-2-challenged MDMs compared to mock-challenged MDMs at different times post-challenge, using RT2 Proﬁler Human Innate and Adaptive
Immune Response 96-well Array. Fold changes in the gene expression were determined via Qiagen’s RT2 Proﬁler analysis software (n=4 donors). (A) IPA was
performed with upregulated or downregulated genes to identify putative network interactions involved in SARS-CoV2-MDM interactions. Upregulated genes are
shaded red with darker shade indicating higher upregulation, while green shades denote downregulation in gene expression. Solid grey lines indicate direct
interactions, while dotted grey lines correspond to indirect interactions. (B) Functional and pathway enrichment analysis of transcriptomic dataset was performed
using GO-term, KEGG, and Reactome analyses at different time points post-infection. Different immune and inﬂammation-related biological processes and pathways
affected in SARS-CoV-2-challenged MDMs were plotted as a bar chart compared to mock-challenged MDMs.
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pathway-linked genes. Furthermore, no additive or synergistic
IFN activity was detected in the control and SARS-CoV-2challenged monocytes treated with poly(I:C) (Figure 3B).
Taken together, the data demonstrate that SARS-CoV-2-MDM
interactions do not affect IFN activities. To afﬁrm this, we
evaluated the protein expression level of IFN-a and IFN-b in
SARS-CoV-2 exposed MDMs at days 1, 3, and 5 post-exposure.
Similar to IFN activity, no IFN-a or IFN-b proteins were
produced in the SARS-CoV-2-challenged MDMs more than
mock-challenged cells (Figure 3C). Altogether, our data
demonstrate that SARS-CoV-2 exposure of MDM does not
trigger IFN activity or protein production in human
monocytes-macrophages.

signaling, IFN-g signaling, TICAM1-dependent activation of
IRF3/IRF7, TRAF3-dependent IRF activation pathway, and
TRAF6 mediated IRF7 activation (Figure 2B). The interacting
proteins involved in the screened innate and adaptive immunerelated genes were also identiﬁed using STRING analysis of their
interaction networks (Supplementary File 4).

SARS-CoV-2 Monocyte-Macrophage
Engagement and Failed Induction
of IFN Activity
To determine whether exposure to the SARS-CoV-2 can trigger
antiviral IFN activities in human macrophages, culture
supernatants were collected at different times post-viral
exposure and assayed in VSV-challenged MDBK cells. Notably,
no type I IFN activity was observed in SARS-CoV-2-challenged
MDM cultures at different time intervals following viral
challenge (Figure 3A). These data stand in contrast to the
transcriptomic results, which displayed increases in IFN

Proteomic Proﬁles of SARS-CoV-2Challenged MDMs
In attempts to elucidate the mechanisms of the MDM response
against the SARS-CoV-2 challenge, we obtained the proteome

A

B

C

FIGURE 3 | SARS-CoV-2 does not induce IFN activity in monocytes-macrophages. (A) MDMs were infected with SARS-CoV-2 (MOI=0.01) and the culture
supernatants were collected at days 1, 3, and 5 post-infection. The collected culture supernatants were used to assess IFN activity in VSV-challenged bovine MDBK
cells. Recombinant human IFN-a was used as standard (64 U/ml). 2-fold dilution was used for different conditions. (A.i) Experimental timeline. (A.ii) Representative
images of IFN activity assay plates. (B) No additive or synergistic responses in poly(I:C)-induced IFN activity between control and SARS-CoV-2-challenged
monocytes. Suspended monocytes were treated with 100 mg/ml poly(I:C) overnight before or after the infection with SARS-CoV-2 (MOI=0.01) for 4 h. (B.i) Experimental
timeline. (B.ii) Representative images of IFN activity assay plates. (C) Western blot analysis was performed to determine expression of IFN-a and IFN-b in cell lysates at
different times after viral exposure. Representative immunoblot and densitometric quantiﬁcation are shown. All experiments were done at least twice, and one representative
image is shown. (C) Data represent mean ± SEM (n=3 donors). Statistical signiﬁcance between the groups was determined with unpaired Student’s t-test and p < 0.05
was considered signiﬁcant.
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virus exposed macrophages compared to that of mockchallenged cells using SARS-CoV-2 proteome on day 5
following viral exposure (Supplementary File 9) showed that
SARS-CoV-2 spike glycoprotein was signiﬁcantly expressed
(1.48-fold, p = 0.032). This conﬁrmed the surprising virion
persistence in MDMs and delayed viral clearance following the
infection (Figure 1C.iii). Overall, these results support
transcriptomic, IFN activity, and protein evaluations that
demonstrated attenuated IFN responses and delayed viral
clearance in SARS-CoV-2-challenged MDMs.

proﬁles from lysates of viral exposed macrophages and compared
those to non-exposed counterparts using the homo sapiens
proteome. On deﬁned days after viral exposure, the expression
of 4049, 4296, and 4246 proteins were identiﬁed and quantiﬁed
using differential proteomic tests on days 1, 3, and 5, respectively
(Supplementary File 5). Amongst total identiﬁed proteins, 1776,
1372, and 2448 proteins were signiﬁcantly differentially
expressed (p ≤ 0.05 and fold change ≥ 2), on days 1, 3, and 5,
respectively, after viral challenge (Supplementary File 6).
Volcano plots depicting differentially expressed proteins in
SARS-CoV-2-challenged MDMs compared to controls are
shown in Supplementary Figure 4. To obtain a detailed
understanding of changes in the MDM proteomic proﬁle after
the viral challenge, we performed functional and pathway
enrichment analyses of differentially regulated proteins in
virus-challenged MDMs at different times. Amongst total
proteins altered on day 1, only 5% were involved in negative
regulation of inﬂammatory response to an antigenic stimulus. In
contrast, on days 3 and 5, 38.1% and 23.53% of altered proteins,
respectively, belonged to myeloid cell activation involved in
immune responses (Figure 4A). Immune processes of each
function indicated in pie charts include, but are not limited to,
activation of the innate immune response, myeloid cell
activation, innate immune response activating signal
transduction, and innate immune response activating cell
surface receptor signaling pathway (Figure 4A and
Supplementary File 7). All indicated activated immune and
inﬂammatory responses in MDMs upon viral challenge.
Additionally, viral exposure induced changes in biological
processes related to the endoplasmic reticulum (ER) and
mRNA on days 1 and 3 after challenge. With positive fold
changes, the enriched biological processes included protein
localization to ER, protein targeting to ER, regulation of
mRNA metabolic process, nuclear-transcribed mRNA catabolic
process, and mRNA splicing via spliceosome (Supplementary
File 8). Similarly, on days 1 and 3 after the viral challenge,
Reactome analysis depicted enrichment of processes related to
RNA processing, with positive fold change, including rRNA
processing in the nucleus and cytosol and mRNA splicing
(Supplementary File 8). Moreover, KEGG pathway analysis
showed an enrichment of ribosome function as a pathway of
genetic information processing and translation on day 1.
Similarly, the molecular function of a structural constituent of
the ribosome was enriched with positive fold change on day 1
(Supplementary File 8). Interestingly, GO-term analysis showed
robust enrichment of different immune responses such as
complement activation, humoral immune response, adaptive
immune response, and regulation of inﬂammatory response
with negative fold changes suggesting dysregulated immune
responses to SARS-CoV-2 in MDMs (Figure 4B). Importantly,
STRING analysis of PPIs showed enrichment of IFN-related
interaction networks such as “IFN signaling and positive
regulation of RIG-I signaling pathway” and “IFN-a/b signaling
and IFN-g signaling”, with negative fold changes, suggesting
dysregulated IFN responses induced by SARS-CoV-2 (Figure 4B
and Supplementary File 8). Notably, the proteome proﬁle of
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Integrated Transcriptomic and Proteomic
Data Analyses of SARS-CoV-2Challenged MDMs
The overlapping genes between the transcriptomic and
proteomic datasets were identiﬁed and illustrated in
Supplementary File 10. Venn diagrams show the number of
genes identiﬁed in transcriptomic and proteomic datasets and
the number of overlapped genes in both datasets at different time
points following the virus challenge was calculated
(Supplementary Figure 5). Additionally, Pearson’s product
moment correlation coefﬁcient between transcriptomic and
proteomic expression fold change for 10 IFN pathway-related
genes (Supplementary File 11) on days 1, 3, 5 following the virus
challenge. These 10 genes were identiﬁed based on the
transcriptomic data gene-enrichment analysis that showed that
these genes are matched to their corresponding proteins in the
proteomic dataset for IFN receptor activity, IFN-a/b signaling,
IFN-g signaling, regulation of IFN-a signaling, regulation of
IFN-g receptor activity, and regulation of IFN-g receptor
binding. Three genes (HLA-A, STAT1, and TYK2) showed
negative correlation between transcription and translation data
while the other genes showed positive correlation (Table 1 and
Supplementary Figure 6). Many are not signiﬁcant, probably
due to the few data points. Only IRF3 showed signiﬁcant linear
relationship between transcriptomic and proteomic detection.
Interestingly, in accordance with the transcriptomic data, on day
5 following the viral challenge the proteomic data showed
upregulated IFNAR1 and MX1 protein levels (1.67 and 1.34fold with p = 0.0003 and 0.11, respectively). This suggests the
possibility of commencement of IFN antiviral response late after
viral challenge, which could restrict the viral replication in virus
challenged MDMs.

DISCUSSION
MPs are the ﬁrst line of host defense against viral infection (9).
These sentinel cells interact with SARS-CoV-2 to deﬁne COVID19 pathogenesis. That includes, but is not limited to, CSS, ARDS,
and multiorgan dysfunction (5). As a ﬁrst line defense
mechanism, the initial virus-MP interaction following the entry
of the pathogenic virus into host cells represents a critical
determinant for infectivity and pathogenesis (42–44). To this
end, we have better deﬁned such virus-host cell interactions and
determined relationships between ACE2 receptor expression and
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A

B

FIGURE 4 | Proteomic proﬁle of SARS-CoV-2-challenged MDMs. (A) Gene enrichment analysis was performed using Cytoscape in conjunction with the plug-in
ClueGO at different times after viral exposure. Pie charts representing the distribution of identiﬁed differentially expressed proteins according to observed immune
processes and bar charts demonstrating the speciﬁc processes that correspond to their classiﬁcation. The same color key used in the pie charts is applied in the bar
charts. (B) Functional and pathway enrichment analyses of proteomic dataset were performed using GO annotation, KEGG, Reactome GSEA, and STRING analyses
at different time points post-infection. Different immune-related biological processes and PPI networks affected in SARS-CoV-2-challenged MDMs were plotted as a
bar chart compared to mock-challenged MDMs.

restrictive without evidence of viral replication and balances
pro- and anti-inﬂammatory processes with a unique cell
signature. The resulting signature deﬁnes the pathways towards
the major cause for morbidity and mortality in COVID-19: the
CSS leading to ARDS and other multi-organ failures. The speciﬁc
lack of induction of IFN also serves to deﬁne a speciﬁc
monocyte-macrophage-virus phenotype during both early and
progressive infection (17, 48). The data set paralleled the lack of
viral clearance noted to 14 days after SARS-CoV-2 exposures. All
underline the persistence of pro-inﬂammatory activities in virus-

monocyte-macrophage differentiation during restrictive SARSCoV-2 infection without evidence of viral replication. Like other
viral infections, we reasoned that monocytes would respond with
an elevated expression of pro-inﬂammatory molecules and
antiviral responses. Indeed, this has already been reported for
inﬂuenza, Chikungunya, herpes, Zika, and lentiviral infections
that include human immunodeﬁciency virus type one (HIV-1)
and herpes viruses (36, 37, 45–47). Each elicits profound
inﬂammation during early viral infection. However, unlike
other known viral infections, SARS-CoV-2 infection is
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TABLE 1 | Pearson’s product moment correlation coefﬁcient of IFN pathwayrelated genes.
Gene/Protein

macrophages up to two weeks after the viral challenge
underscoring any continuity of immune responses.
SARS-CoV-2 restrictive infection without evidence of viral
replication likely results from intracellular mechanisms induced
upon MP activation. Human coronaviruses can infect human
peripheral blood mononuclear cells leading to cell activation and
aberrant production of pro-inﬂammatory mediators with
increased chemoattraction (53–55). In particular, virus-exposed
monocytes-macrophages can serve as perpetrators for virusinduced inﬂammatory responses within different body organs,
as seen by the abundance of pro-inﬂammatory macrophages in
bronchoalveolar lavage ﬂuid obtained from severe COVID-19
cases (56). The MP pro-inﬂammatory factors can contribute to
local tissue inﬂammation and systemic inﬂammatory responses
that characterize cytokine storm (9). In the current study, the
transcriptomic proﬁle of SARS-CoV-2-challenged MDMs
demonstrated increased mRNA expression of multiple proinﬂammatory molecules, including IL-6, TNF-a, IL-1a, IL17A,
IL8, CSF2, CCL2, CCL5, NLRP3, and IL-1b upon the virus
exposure. Our data conﬁrmed previous reports which showed
excessive production of pro-inﬂammatory cytokines and
chemokines in the SARS-CoV-2-exposed MPs (17, 18, 50). In
humans, TLR8 is more prominently present in myeloid lineage
cells such as monocytes and neutrophils (57). The prominent
ligand for TLR7 and TLR8 is viral single-stranded RNA (ssRNA)
(58) and, more speciﬁcally for TLR8, its RNAse T2 degradation
products (59). GU-rich ssRNA derived from SARS-CoV-2,
SARS-CoV-1, and HIV-1 was found to trigger a TLR8dependent pro-inﬂammatory cytokine response from human
macrophages in the absence of pyroptosis, with GU-rich RNA
from the SARS-CoV-2 spike protein triggering the greatest
inﬂammatory response (60). In our study, the slight
upregulation of TLR8 gene expression on day 5 following viral
challenge agrees with a recent study demonstrating that lung
TLR8 contributes to the cytokine storm during COVID-19
disease (61). In parallel, our data displayed enrichment of
different inﬂammation-related pathways such as IL-17, NF-kB,
and TNF signaling pathways, following viral exposure. IL-17 is
known for its pivotal role in inducing and mediating proinﬂammatory responses and its involvement in different
inﬂammatory autoimmune diseases (62). NF-kB serves as a
central mediator of inﬂammation since the DNA binding site
for NF-kB was found in the promoter regions of multiple proinﬂammatory molecules (63). Thus, the activation of NF-kB with
other pro-inﬂammatory transcription factors leads to the
transcription of several pro-inﬂammatory molecules such as
IL-1b, inducible nitric oxide synthase (iNOS), and TNF-a (64,
65). In addition, the transcriptome of SARS-CoV-2-challenged
MDMs showed enrichment of multiple immune-related
biological processes, molecular functions, and signaling
pathways such as positive regulation of immune response, cell
surface receptor signaling pathway, cytokine activity, chemokine
activity, TLR signaling pathway, and NOD-like receptor
signaling pathway, demonstrating cell activation of MDMs
after viral exposure. Notably, the proteome of virus-challenged
macrophages revealed the dysregulation of different immune

Transcriptomic - Proteomic Correlation
Pearson product moment analysis

B2M
DDX58
HLA-A
HLA-E
ICAM1
IFNAR1
IRF3
MX1
STAT1
TYK2

r

p value

0.8691
0.8747
-0.0844
0.0214
0.6811
0.5154
0.9982
0.6539
-0.0667
-0.5610

0.329
0.322
0.946
0.863
0.523
0.655
0.038
0.546
0.958
0.621

r: Pearson correlation coefﬁcient.

challenged macrophages and the pathways for how persistence of
innate immune responses could occur and lead to devastating
lung damage preceding to the death of an infected host.
Herein, we show increased expression of viral receptor ACE2
during monocyte-macrophage differentiation. Interestingly,
further induction of ACE2 expression by captopril, a wellknown ACE inhibitor, was observed. Captopril induces a
reduction of angiotensin II, which increases ACE2 expression
and activity. This occurs through angiotensin type 1 receptordependent ACE2 internalization followed by lysosomal
degradation (49). However, the observed upregulation of ACE2
expression failed to affect infection with SARS-CoV-2. Despite
infection of MDMs with SARS-CoV-2 when ACE2 receptor
expression peaked, the infection remained restrictive without
evidence of viral replication in agreement with previous studies
which showed that infection of human MDMs with SARS-CoV2 was not productive (17, 18, 50). In the current study, the
upregulation of STAT1, IFNAR1, and MX1 at the transcriptome
level in addition to the upregulation of both IFNAR1 and MX1 at
the proteome level on day 5 after viral challenge suggests the
possibility of commencement of type I IFN antiviral response at a
late time point after viral exposure and the contribution of MX1
to the absence of viral replication seen with restrictive infection
in SARS-CoV-2-challenged human macrophages (38).
Furthermore, the previous study suggests that type-I IFNs are
commonly regulated during SARS-CoV-2 infection of cell lines
observed within 24 hours of virus infection (51). These data
further support the results observed following the viral infection
in human macrophages. The type-I IFN response was seen
within one day of viral macrophage exposure. The inability of
captopril to increase the susceptibility of MDM infection with
SARS-CoV-2 is in accordance with a recent study indicating that
treatment of human alveolar type-II pneumocytes with captopril
induced upregulation of ACE2 expression and counteracted
drug-induced reduction of SARS-CoV-2 spike protein entry
(34). This occurred through inhibition of A disintegrin and
metalloprotease 17 (ADAM17), which has been shown to play
an essential role in ACE2 shedding and viral entry into the cells
(52). Nonetheless, viral particles were present inside
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cytokine and chemokine production, and attenuated IFN
responses. Each and all imply dysfunction of the innate
immune system after viral exposure. Transcriptomic and
proteomic proﬁles of SARS-CoV-2-challenged MPs provide
signatures for understanding COVID-19 pathogenesis. The
lack of adequate antiviral innate immune responses in the
midst of cytokine storm heralds an absence of viral infection
control that exacerbates clinical manifestations and contributes
to end-organ damage for COVID-19-related morbidities
and mortalities.

processes such as regulation of inﬂammatory response,
complement activation, and linked adaptive and humoral
immune responses. Overall, our ﬁndings demonstrate that
MDM activation by SARS-CoV-2 is associated with
exaggerated inﬂammatory responses and dysregulated
immune activities.
Signiﬁcantly, SARS-CoV-2 induced an attenuated MP IFN
response, as the transcript expression of type I (IFN-a1 and
IFN-b1) and type II (IFN-g) IFNs in the virus-challenged cells
increased early after exposure but returned to or below normal
levels at later times. Our ﬁndings are consistent with previous
reports depicting a dysregulated IFN response in SARS-CoV-2challenged MDMs and alveolar macrophages (17, 48). This
attenuated IFN response provides a possible mechanism for
delayed viral clearance from cells up to 2 weeks after infection.
Similarly, our study showed the inability of SARS-CoV-2 to induce
IFN activity or production in MDMs, as illustrated by the failure of
culture supernatants of infected cells to provide protection against
the cytopathic effects induced by VSV in MDBK cells as well as
unchanged levels of IFN-a and IFN-b after the virus challenge.
These ﬁndings follow a recent study that demonstrated the
absence of IFN induction in the alveolar macrophages
challenged with SARS-CoV-2 (48). A possible explanation is the
presence of a cap structure on the viral genome. The
Coronoviridae family contains this structure enabling the virus
to evade recognition by PRRs and prevent the host innate immune
response mediated by the RIG-I/mitochondrial antiviral-signaling
(MAVS) pathway that recognizes ssRNAs without a cap structure
(66, 67). Moreover, different SARS-CoV-2 proteins were found to
antagonize type I IFN production through other mechanisms (68).
SARS-CoV-2 nonstructural protein 6 (nsp6) binds TANK binding
kinase 1 (TBK1) to suppress IRF3 phosphorylation, and nsp13
binds and blocks TBK1 phosphorylation. In addition, open
reading frame 6 (ORF6) binds importin Karyopherin a 2 to
inhibit IRF3 nuclear translocation, and ORF7b prevents STAT1
phosphorylation and nuclear translocation, consequently
inhibiting the transcription of multiple IFN stimulated genes
(ISGs) which possess antiviral functions (68). In parallel, the
negative fold change of IFN-related interaction networks: “IFN
signaling and positive regulation of RIG-I signaling pathway” and
“IFN-a/b signaling and IFN-g signaling” indicates dysregulated
IFN responses in the SARS-CoV-2-challenged MDMs. Thus far,
our data suggest an aberrant IFN response induced by SARS-CoV2 in human MDMs. Early IFN induction was halted at the
transcriptional level one day post-infection. It did not proceed
to the translational level because of SARS-CoV-2 proteins found to
antagonize type I IFN production (68). Thus, we postulate that
aberrant IFN responses in the face of a robust inﬂammatory
environment presage a lack of viral infection control and multiorgan damage in COVID-19 (3).
In summary, we demonstrate that persistence of SARS-CoV-2
components in macrophage infection triggers a unique signature
of inﬂammatory responses despite the absence of viral
replication. This includes combinations of restrictive infection
with delayed viral clearance, excessive pro-inﬂammatory
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Supplementary Figure 2 | Kinetic growth of SARS-CoV-2 in human monocytemacrophage. MOIs used for SARS-CoV-2 challenge in MDMs were 0.001, 0.01,
and 0.1. Number of virus genome equivalents/ml was measured in culture
supernatants by RT-qPCR on day 11 (n=4 donors).
Supplementary Figure 3 | Fold changes of immune response genes in SARSCoV-2-challenged MDMs. Heat map of fold changes in the expression of 84 genes
speciﬁc for human innate and adaptive immune responses in SARS-CoV-2challenged MDMs compared to mock-challenged MDMs at different time points
after the infection, determined using RT2 Proﬁler Human Innate and Adaptive
Immune Response 96-well Array. Fold changes were determined via Qiagen’s RT2
Proﬁler analysis software (n=4 donors).
Supplementary Figure 4 | Differential proteomic analysis of SARS-CoV-2challenged MDMs. Volcano plots showing the fold change plotted against the P
value highlighting signiﬁcantly changed proteins (red – upregulation and green –
downregulation; p ≤ 0.05 and an absolute fold change ≥ 2) in SARS-CoV-2challenged MDMs compared to mock-challenged MDMs at different time points
(n=4 donors). The vertical lines correspond to the absolute fold change of 2, and the
horizontal line represents a p value of 0.05.
Supplementary Figure 5 | Venn diagrams showing overlap in quantiﬁed genes
and proteins of SARS-CoV-2-challenged MDMs. Overlapping genes between
transcriptomic and proteomic data (n=4 donors) were identiﬁed at deﬁned time
points after viral challenge.
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Supplementary Figure 6 | Correlation analyses of IFN pathway-related genes.
For all correlation analyses, 95% conﬁdence intervals were used. Data are displayed
as scatter plots and correlations were determined using Pearson product moment
correlation coefﬁcients and were adjusted for FDR.

Supplementary Figure 1 | Representative histograms of ACE2, CD14, and
CD16 in human monocyte-macrophages. Expression of SARS-CoV-2 cell entry
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